Rooshi Nathwani

680 total citations
14 papers, 324 citations indexed

About

Rooshi Nathwani is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Rooshi Nathwani has authored 14 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 7 papers in Hepatology and 3 papers in Oncology. Recurrent topics in Rooshi Nathwani's work include Liver Disease and Transplantation (7 papers), Liver Disease Diagnosis and Treatment (6 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Rooshi Nathwani is often cited by papers focused on Liver Disease and Transplantation (7 papers), Liver Disease Diagnosis and Treatment (6 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Rooshi Nathwani collaborates with scholars based in United Kingdom, Switzerland and Russia. Rooshi Nathwani's co-authors include Mark Thursz, Ameet Dhar, Evangelos Triantafyllou, Charalambos G. Antoniades, Wafa Khamri, Arjuna Singanayagam, Benjamin H. Mullish, Pinelopi Manousou, Oltin T. Pop and Roberta Forlano and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Gut.

In The Last Decade

Rooshi Nathwani

13 papers receiving 322 citations

Peers

Countries citing papers authored by Rooshi Nathwani

Since Specialization

Citations

This map shows the geographic impact of Rooshi Nathwani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rooshi Nathwani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rooshi Nathwani more than expected).

Fields of papers citing papers by Rooshi Nathwani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rooshi Nathwani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rooshi Nathwani. The network helps show where Rooshi Nathwani may publish in the future.

Co-authorship network of co-authors of Rooshi Nathwani

This figure shows the co-authorship network connecting the top 25 collaborators of Rooshi Nathwani. A scholar is included among the top collaborators of Rooshi Nathwani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rooshi Nathwani. Rooshi Nathwani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Suppressor CD4⁺T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis 2021 ·Gut ·Wafa Khamri, Cathrin Gudd, Tong Liu, Rooshi Nathwani, (unknown), (unknown), Thomas Barbera, Francesca M. Trovato, Lucia Possamai, Evangelos Triantafyllou, Rocio Castro Seoane, Fanny Lebossé, Arjuna Singanayagam, (unknown), Christine Bernsmeier, Sujit Mukherjee, Mark McPhail, Chris J. Weston, Charalambos G. Antoniades, Mark Thursz	7
2	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 2021 ·Journal of Hepatology ·Cathrin Gudd, Lewis Au, Evangelos Triantafyllou, Benjamin Shum, Tong Liu, Rooshi Nathwani, (unknown), Sujit Mukherjee, Ameet Dhar, Kevin Woollard, (unknown), David J. Pinato, Mark Thursz, Robert Goldin, Martin Gore, James Larkin, Wafa Khamri, Charalambos G. Antoniades, Samra Turajlic, Lucia Possamai	43
3	Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use 2021 ·SHILAP Revista de lepidopterología ·Rooshi Nathwani, Benjamin H. Mullish, (unknown), Alexander J. Cole, Nowlan Selvapatt, Ameet Dhar	2
4	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19 2020 ·PLoS ONE ·Roberta Forlano, Benjamin H. Mullish, Sujit Mukherjee, Rooshi Nathwani, (unknown), Peter Crook, R. Judge, (unknown), Paul Middleton, Anna Daunt, Pablo N. Perez‐Guzman, Nowlan Selvapatt, Maud Lemoine, Ameet Dhar, Mark Thursz, Shevanthi Nayagam, Pinelopi Manousou	51
5	A Review of Liver Fibrosis and Emerging Therapies 2020 ·European Medical Journal ·Rooshi Nathwani, Benjamin H. Mullish, (unknown), Roberta Forlano, Pinelopi Manousou, Ameet Dhar	8
6	Non-Alcoholic Fatty Liver Disease and Vascular Disease 2020 ·Current Vascular Pharmacology ·Roberta Forlano, Benjamin H. Mullish, Rooshi Nathwani, Ameet Dhar, Mark Thursz, Pinelopi Manousou	11
7	CD8+ T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction 2019 ·EBioMedicine ·Fanny Lebossé, Cathrin Gudd, (unknown), Arjuna Singanayagam, Rooshi Nathwani, Evangelos Triantafyllou, Oltin T. Pop, (unknown), Sujit Mukherjee, Tie Zheng Hou, Alberto Quaglia, Fabien Zoulim, Julia Wendon, Ameet Dhar, Mark Thursz, Charalambos G. Antoniades, Wafa Khamri	69
8	Current and future pharmacological therapies for managing cirrhosis and its complications 2019 ·World Journal of Gastroenterology ·(unknown), Rooshi Nathwani, Roberta Forlano, Pinelopi Manousou, Benjamin H. Mullish, Ameet Dhar	28
9	THU-052-Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure 2019 ·Journal of Hepatology ·Arjuna Singanayagam, (unknown), Evangelos Triantafyllou, Christine Bernsmeier, (unknown), (unknown), Vishal Patel, Fanny Lebossé, Rooshi Nathwani, Roger Atkinson, Ameet Dhar, Michael A. Heneghan, Georg Auzinger, Wafa Khamri, David Adams, Julia Wendon, Mark Thursz, Mark McPhail, Harry N. Antoniades	1
10	PTH-106 Plasma S100A8/A9: a novel mechanistic biomarker in innate immune activation in acute-on-chronic liver failure 2018 ·Arjuna Singanayagam, Rooshi Nathwani, Evangelos Triantafyllou, (unknown), Anjan Dhar, Mark McPhail, Christine Bernsmeier, Julia Wendon, (unknown)	1
11	PWE-085 Immune checkpoint inhibitor induced acute liver injury – a national cohort study 2018 ·Rooshi Nathwani, Lewis Au, (unknown), Tania Tillett, Rebecca Bowen, Lavinia Spain, (unknown), Michael Backhouse, (unknown), Robert M. Morrison, Troy J. Cross, (unknown), Robert Goldin, Martin Gore, James Larkin, Samra Turajlic, Charalambos Antoniades	1
12	Pathogenesis, clinical evolution and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: A multicentre study 2018 ·Annals of Oncology ·Lewis Au, Rooshi Nathwani, Lucia Possamai, (unknown), Tania Tillett, Rebecca Bowen, Lavinia Spain, Jennifer Thomas, Michael Backhouse, (unknown), Rebecca Morrison, Tim Cross, Cristan Herbert, Robert Goldin, Martin Gore, James Larkin, Charalambos Antoniades, Samra Turajlic	1
13	CD14 ⁺ CD15 ⁻ HLA-DR ⁻ myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure 2017 ·Gut ·Christine Bernsmeier, Evangelos Triantafyllou, (unknown), Fanny Lebossé, Arjuna Singanayagam, Vishal Patel, Oltin T. Pop, Wafa Khamri, Rooshi Nathwani, Robert Tidswell, Chris J. Weston, David Adams, Mark Thursz, Julia Wendon, Charalambos G. Antoniades	100
14	A complicated case of anticoagulation 2013 ·BMJ Case Reports ·Rooshi Nathwani	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact